查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848861

臨床試驗影像市場按產品/服務、模式、治療領域和最終用戶分類 - 全球預測 2025-2032

Clinical Trial Imaging Market by Product & Service, Modality, Therapeutic area, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臨床試驗影像市場將成長至 23.8 億美元，複合年成長率為 6.92%。

關鍵市場統計數據
基準年 2024 13.9億美元
預計年份：2025年 14.8億美元
預測年份 2032 23.8億美元
複合年成長率 (%) 6.92%

本文簡要概述了臨床試驗影像技術如何發展成為一項綜合性的策略能力，從而加速方案決策並增強監管機構的信心。

臨床試驗影像已發展成為現代藥物研發的戰略支柱，它整合了先進的成像技術、分析方法和操作流程，從而支持客觀終點、安全性監測和患者分層。近年來，影像的應用已不再局限於輔助測量，而是成為方案設計、適應性試驗策略和監管互動中的關鍵組成部分。這一轉變反映了影像硬體技術的進步，以及能夠協調不同中心和供應商提供的影像資料集的軟體工具的同步發展。

因此，臨床試驗贊助者和研究者越來越重視研究計畫早期階段的影像策略。如今，跨職能團隊與生物統計和臨床營運部門協同工作，協調影像物流、供應商選擇、品質保證和數據管治，以減少返工並加快結果解讀。由此，一種分層式的影像方法——包括影像模式選擇、集中式閱片流程和綜合分析——已成為最佳實踐，其核心在於可重複性和可解釋性。

從各自獨立的影像處理操作向一體化影像處理專案的轉型需要有意識的變革管理、對供應商監管的投入以及互操作系統的採用。如果執行得當，這些投入將帶來更可靠的終點指標、簡化監管申報流程，並增強臨床研究人員和相關人員（包括監管審查人員）的信心。本執行摘要探討了影響市場格局的因素、收費標準的影響、市場細分洞察、區域發展、競爭動態、可操作的建議、調查方法的嚴謹性，以及如何取得完整報告以獲取更深入的說明。

融合技術、監管核准和不斷演變的營運模式如何再形成臨床試驗影像生態系統和決策路徑

臨床試驗影像領域正經歷一場變革性的轉變，其驅動力包括技術融合、監管機構對客觀終點的重視以及不斷演進的運作模式。人工智慧和進階分析技術如今已能有效補充傳統的放射學評估，提供自動分割、定量生物標記提取和異常檢測等功能，從而降低變異性並提高對治療效果的敏感性。隨著這些功能的普及，申辦者和影像服務供應商正在採用混合工作流程，將自動化預處理與盲法專家審查相結合，以確保臨床有效性。

同時，監管機構對基於影像學終點指標的認可度日益提高，這些指標需採用標準化的採集和檢驗的分析流程，從而鼓勵申辦方在試驗方案生命週期的早期階段就納入影像學策略。監管機構的這種認可正在推動對影像核心實驗室、集中式閱片模式和嚴格的品質保證框架的投資。在營運層面，供應商整合和平台統一化正在顯著降低多中心、全球性試驗的複雜性並提高資料可追溯性。

最後，支付方和衛生經濟相關人員越來越重視影像生物標記的實際應用價值，這影響終點選擇和長期證據規劃。這種轉變迫使醫療機構重新評估自身能力，優先考慮可互操作系統，並建立夥伴關係，以加速部署符合臨床和商業性目標的強大影像專案。

針對近期關稅調整對診斷影像專案設備流通、供應商選擇和供應鏈彈性造成影響的實際考量和營運調整

近期一些地區對醫療設備、零件及相關服務徵收的關稅，為臨床試驗影像處理流程帶來了新的考量，尤其對於依賴跨境運輸掃描儀、配件及專用硬體的國際研究而言更是如此。關稅帶來的成本壓力可能會影響設備採購時機、維護計畫以及現場服務與集中服務等決策。事實上，臨床試驗贊助者和影像診斷服務機構正在權衡各種利弊，例如本地採購設備、將影像判讀外包給區域核心實驗室，或利用雲端託管來最大限度地減少人員流動。

為此，許多相關人員探索了在地採購策略，並協商簽署了長期服務協議，以在保證資料品質和合規性的同時，穩定整體擁有成本。這些策略強調與區域供應商建立合作關係，以減少資本設備跨境運輸的頻率，並提供及時的技術支援和遵守標準化的採購通訊協定。此外，供應鏈路線的調整也促使採購、臨床營運和供應商夥伴關係團隊之間進行更緊密的合作，以確保正在進行的臨床試驗影像能力的持續性。

重要的是，各公司也在審查合約條款，包括關稅緊急條款和靈活的服務等級協議，以應對潛在的貿易中斷。關稅雖然增加了複雜性，但也促使企業制定更靈活的營運計畫、建構多元化的供應商網路，並更注重區域內的能力建設，從而保障臨床實驗的進度和數據的完整性。

透過深度細分洞察，使產品和服務、成像方式、治療重點和最終用戶期望與業務和臨床需求保持一致。

以細分市場為重點的分析揭示了產品/服務連續體、成像方式、治療領域和最終用戶類別中清晰的優先事項和營運需求。依產品/服務分類，市場研究分為服務及軟體兩類，其中服務又細分為影像操作服務、先導化合物分析服務、系統及技術支援服務及試驗設計及諮詢服務。以影像方式分類，包括電腦斷層掃描（CT）、超音波心動圖、磁振造影）、正子斷層掃描（PET）、超音波和X光，每種影像方式都有其獨特的成像通訊協定、品管和分析需求，這些都會影響供應商的選擇和訓練要求。

按治療領域分類，此生態系涵蓋內分泌學、免疫學、感染疾病、神經病學和腫瘤學。腫瘤學試驗通常需要多參數成像和長期隨訪，而神經病學試驗則側重於標準化的認知和結構成像終點。按最終用戶分類，該生態系統包括學術和政府研究機構、生物技術公司、委外研發機構和製藥公司，每個機構都有各自的採購時間表、監管要求和創新動力。例如，學術中心通常優先考慮調查方法的嚴謹性和新型生物標記，而商業贊助商則通常優先考慮可擴展性、成本可預測性和結果讀取時間。

綜上所述，這些細分維度凸顯了靈活的服務架構、特定模式的標準操作規程以及客戶參與模式的重要性，這些模式能夠使技術能力與治療目標和最終用戶需求保持一致。策略供應商和申辦者若能依照這些維度調整其服務，將實現更高的營運效率，並更好地與臨床試驗目標相契合。

關鍵全球區域的基礎設施、監管差異和營運能力如何影響臨床試驗影像策略和執行

區域動態對影像操作、供應商生態系統以及與監管機構的互動有顯著影響，不同區域的能力、基礎設施和協作網路模式各不相同。在美洲，先進的影像基礎設施、龐大的影像核心實驗室以及高度普及的數位化工作流程為複雜的多中心臨床試驗提供了支援。然而，營運挑戰包括地理距離、各中心能力差異以及在異質性臨床環境中實現高度標準化的必要性。因此，申辦方通常傾向於採用集中閱片與區域技術支援相結合的方式，以平衡品質和物流。

在歐洲、中東和非洲，監管環境的多樣性和影像基礎設施的差異，使得通訊協定的嚴格協調、標準操作規程的跨語言翻譯以及嚴謹的設施認證流程成為必要。該地區擁有強大的學術中心和成熟的合作網路，如果申辦方投資於前期培訓和平台互通性，則有利於進行跨國研究。此外，區域供應商通常能夠提供寶貴的本地技術支持，並加快設備部署速度。

對影像硬體的快速投資、臨床研究能力的拓展以及本地CRO能力的提升，使得亞太地區進行大規模臨床試驗的吸引力日益增強。然而，臨床實踐模式、資料保護框架以及影像技術應用率的差異，要求制定獨特的影像策略，重點關注早期中心評估和擴充性的雲端基礎解決方案。任何地區的成功都取決於積極的區域參與、標準化的資料收集通訊協定以及健全的品質保證體系，這些體系能夠彌合區域差異，並確保匯總分析的資料完整性。

競爭格局洞察：專業供應商、軟體創新者、核心實驗室和CRO聯盟如何為臨床試驗建立差異化的端到端影像解決方案

臨床試驗影像領域的競爭格局反映了專業服務供應商、軟體創新者、影像核心實驗室和整合供應商聯盟的整合，共同建構了服務交付模式。領先的影像公司透過提供檢驗的閱片平台、特定模態的專業知識和諮詢式研究設計服務來脫穎而出，幫助申辦方將臨床假設轉化為可靠的影像終點。同時，提供可擴展分析、安全雲端儲存和符合監管標準的審核追蹤的軟體公司，正成為多供應商編配和資料管治的核心參與者。

影像服務公司與科技公司之間的夥伴關係十分普遍，從而能夠提供端到端的提案，包括現場培訓、集中閱片和高級後處理。合約研究組織正透過組織或策略聯盟整合影像能力，拓展其服務範圍，為申辦方提供簡化供應商管理的單一供應商解決方案。學術中心和專業研究機構持續貢獻方法創新和檢驗研究，為最佳實踐和監管對話提供資訊。

買方在進行競爭性評估時，應優先考慮檢測模式的過往記錄、檢驗的分析流程、監管合規歷史以及支援全球臨床臨床實驗的營運能力。能夠證明跨模式互通性、透明的品質指標和可自訂服務等級的供應商通常具有競爭優勢。最終，市場更青睞那些能夠降低複雜性、提供可追溯的審核追蹤並將技術交付與臨床目標相結合的合作夥伴。

診斷影像專案領導者可以採取哪些策略措施來互通性、檢驗的分析和早期方案調整，以降低臨床試驗風險並提高數據效用？

產業領導者應採取策略性策略，整合技術投資、嚴格的營運規範和夥伴關係關係，以提升臨床試驗影像計畫的有效性。首先，檢驗互通性，選擇支援標準化採集通訊協定和安全性、審核資料傳輸的平台和供應商。其次，應採用自動化分析作為專家審核的補充，利用經過驗證的演算法加快預處理速度並標記品質問題，同時保持最終終點決策的盲法裁決。

其次，應投資於早期影像策略的製定，將影像專家納入方案設計，並將影像方式的選擇、掃描時機和解讀範式與臨床終點和監管要求相匹配。這種方法可以最大限度地減少返工，並降低影像資料無法讀取或使用的風險。此外，應透過建立區域供應商網路和靈活的合約條款（包括應對關稅相關突發情況和區域設備支援），確保不同地區影像處理能力的連續性。最後，應建立管治機制，強制執行透明的品質指標、定期的實驗室間校準以及明確的影像處理交付課責。透過實施這些措施，申辦者和服務供應商可以減少營運摩擦，提高資料完整性，並加速影像在臨床專案中的轉換應用。

採用嚴格的混合方法，結合相關人員訪談、二手證據綜合和資料三角驗證，確保獲得可靠且可操作的影像學發現。

本研究採用混合方法，以確保研究的嚴謹性、可重複性和對決策者的相關性。調查方法結合了對行業相關人員（包括影像科主任、臨床營運主任和科學顧問）的定性訪談，以及對公開的監管指南、臨床試驗註冊資訊、技術白皮書和同行評審文獻的全面二次分析。主要訪談著重於營運挑戰、供應商選擇標準、特定成像方式的考量因素以及區域實施瓶頸，從而為二次分析結果提供了循證觀點。

為驗證主題的有效性並協調不同觀點，調查團隊採用了資料三角驗證法。他們綜合了程序標準、技術規格以及實際實施中所學到的經驗教訓，並制定了切實可行的建議。品質保證程序包括對訪談記錄進行交叉檢驗、檢查不同資料來源的一致性以及專家同行評審，以確保分析結論的可靠性。在適用的情況下，研究記錄了調查方法的注意事項和假設，以幫助讀者根據研究範圍以及不斷變化的監管和技術環境來解讀研究結果。

最後，這種方法強調了資料來源和解釋步驟的透明度，使讀者能夠追溯結論的來源輸入，並了解營運現實和技術創新如何影響分析框架。

對整合影像策略、檢驗分析和操作穩健性如何決定臨床試驗的成功和證據可靠性進行總結性審查。

臨床試驗影像在證據生成過程中扮演核心角色，它提供客觀、可重複的指標，為臨床決策和監管互動提供支持。先進成像技術、自動化分析和整合服務模式的相互作用，為提高終點敏感度、降低變異性以及加快獲得有效結果創造了機會。同時，成像技術異質性、區域差異以及不斷變化的交易考量所帶來的操作複雜性，需要周密的規劃、供應商管治以及對互操作系統的投資。

展望未來，那些優先將影像策略早期整合到通訊協定設計中、負責任地運用檢驗的分析方法並建立穩健的供應商網路的機構，將能夠更好地利用影像技術作為策略差異化優勢。同時，嚴格的品質保證、透明的績效指標以及與監管機構和科學界相關人員的密切合作，對於將影像數據轉化為可靠的臨床證據仍然至關重要。這些措施將共同強化影像技術在各個治療領域和終端使用者中的作用，從而為臨床計畫和更廣泛的醫療保健系統相關人員帶來更清晰、更可靠的結果。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧演算法整合到腫瘤影像研究中，以實現病灶的自動定量分析
  • 實施雲端基礎的影像資料平台，以支援全球各地臨床試驗中心的分散式工作流程。
  • 開發用於臨床試驗中早期檢測心血管治療效果的定量影像生物標記
  • 新興的PET/MRI混合通訊協定可用於增強神經退化性疾病研究中的多參數評估
  • 在分散式臨床試驗中實施用於遠端患者監護的即時行動成像設備
  • 跨國藥物研發研究中標準化影像終點檢驗的法規結構正在不斷發展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：臨床試驗影像市場（依產品及服務分類）

  • 服務
    • 營運影像服務
    • 分析服務
    • 系統和技術支援服務
    • 測試設計和諮詢服務
  • 軟體

9. 臨床試驗影像市場依影像方式分類

  • 電腦斷層掃描
  • 心臟超音波圖
  • 磁振造影
  • 正子斷層掃描
  • 超音波
  • X光

第10章：依治療領域分類的臨床試驗影像市場

  • 內分泌學
  • 免疫疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第11章 臨床試驗影像市場（依最終使用者分類）

  • 學術和政府研究機構
  • 生技公司
  • 合約研究組織
  • 製藥公司

第12章：按地區分類的臨床試驗影像市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按組別分類的臨床試驗影像市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：各國臨床試驗影像市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alimentiv Inc.
    • Anagram 4 Clinical Trials
    • Biospective Inc.
    • Boston Imaging Core Lab LLC
    • Cardiovascular Imaging Technologies LLC
    • Clario
    • GE HealthCare Technologies Inc.
    • Icon PLC
    • Image Core Lab Private Limited
    • Imaging Endpoints II LLC
    • Ixico PLC
    • Median Technologies
    • Medical Metrics Inc. by Catalent, Inc.
    • Medidata by Dassault Systemes
    • Medpace, Inc.
    • Micron Inc.
    • Perceptive Informatics LLC
    • ProScan Imaging LLC
    • Resonance Health Ltd.
    • Voiant Clinical
    • WCG Clinical, Inc.
Product Code: MRR-501246435DF5

The Clinical Trial Imaging Market is projected to grow by USD 2.38 billion at a CAGR of 6.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.39 billion
Estimated Year [2025] USD 1.48 billion
Forecast Year [2032] USD 2.38 billion
CAGR (%) 6.92%

A concise orientation to how clinical trial imaging has evolved into an integrated, strategic capability that accelerates protocol decisions and regulatory confidence

Clinical trial imaging has matured into a strategic pillar of contemporary drug development, integrating advanced modalities, analytics, and operational workflows to support objective endpoints, safety monitoring, and patient stratification. Over recent years, imaging has expanded beyond a supporting measurement to become a decisive element in protocol design, adaptive trial strategies, and regulatory interactions. This shift reflects both technological advancements in acquisition hardware and the parallel evolution of software tools capable of harmonizing heterogeneous imaging datasets across sites and vendors.

As a result, sponsors and trial operators increasingly prioritize imaging strategy at earlier stages of study planning. Cross-functional teams now coordinate imaging logistics, vendor selection, quality assurance, and data governance in tandem with biostatistics and clinical operations, thereby reducing rework and accelerating readouts. Consequently, a layered approach to imaging-encompassing modality selection, centralized reading paradigms, and integrated analytics-has emerged as best practice where reproducibility and interpretability are critical.

Transitioning from isolated imaging tasks to a unified imaging program requires deliberate change management, investment in vendor oversight, and the adoption of interoperable systems. When executed well, these investments yield more defensible endpoints, streamlined regulatory submissions, and enhanced confidence across stakeholder groups, including clinical investigators and regulatory reviewers. The remainder of this executive summary explores the forces reshaping the landscape, tariff implications, segmentation-driven insights, regional dynamics, competitive activity, actionable recommendations, methodological rigor, and an invitation to procure the full report for deeper guidance.

How converging technologies, regulatory acceptance, and evolving operational models are reshaping the clinical trial imaging ecosystem and decision pathways

The clinical trial imaging landscape is experiencing transformative shifts driven by technology convergence, regulatory emphasis on objective endpoints, and evolving operational models. Artificial intelligence and advanced analytics now complement traditional radiologic assessment by offering automated segmentation, quantitative biomarker extraction, and anomaly detection that decrease variability and enhance sensitivity to treatment effects. As these capabilities become more accessible, sponsors and imaging service providers are adopting hybrid workflows that blend automated pre-processing with blinded expert reads to maintain clinical validity.

Concurrently, regulatory authorities have signaled greater receptivity to imaging-derived endpoints when supported by standardized acquisition and validated analytic pipelines, prompting sponsors to embed imaging strategy earlier in the protocol lifecycle. This regulatory receptivity encourages investments in imaging core labs, centralized reading models, and rigorous quality assurance frameworks. Operationally, there is a pronounced movement toward vendor consolidation and platform unification to reduce complexity and improve data traceability across multi-center, global trials.

Finally, payer and health economics stakeholders increasingly evaluate the real-world applicability of imaging biomarkers, which is influencing endpoint selection and long-term evidence plans. Together, these shifts compel organizations to reassess capabilities, prioritize interoperable systems, and cultivate partnerships that accelerate deployment of robust imaging programs aligned to clinical and commercial objectives.

Practical considerations and operational adaptations driven by recent tariff adjustments that affect equipment flows, vendor selection, and supply chain resilience for imaging programs

The recent imposition of tariffs affecting medical equipment, components, and associated services in some jurisdictions has introduced new considerations for clinical trial imaging operations, particularly in global studies that rely on cross-border shipment of scanners, accessories, and specialized hardware. Tariff-related cost pressures can influence timing for equipment procurement, maintenance scheduling, and decisions around on-site versus centralized services. In practice, sponsors and imaging service organizations evaluate the trade-offs between procuring equipment locally, outsourcing imaging reads to regional core labs, or leveraging cloud-hosted analytics to minimize physical transfers.

In response, many stakeholders have explored localized sourcing strategies and negotiated longer-term service agreements to stabilize total cost of ownership while preserving data quality and regulatory compliance. This strategy reduces the frequency of cross-border movements of capital equipment and emphasizes partnerships with regional vendors that can provide timely technical support and adherence to standardized acquisition protocols. Moreover, shifts in supply chain routing have encouraged closer collaboration between procurement, clinical operations, and vendor management teams to ensure continuity of imaging capacity for ongoing trials.

Importantly, organizations are also reviewing contracting terms to include tariff contingency clauses and flexible service-level agreements that account for potential trade disruptions. While tariff measures introduce complexity, they also motivate more resilient operational planning, diversified supplier networks, and greater emphasis on in-region capabilities that can safeguard trial timelines and data integrity.

Detailed segmentation-driven insights that align product/service offerings, imaging modalities, therapeutic priorities, and end-user expectations to operational and clinical requirements

Segment-focused analysis reveals distinct priorities and operational requirements across the product and service continuum, modalities, therapeutic areas, and end-user categories. Based on Product & Service, market study groups Services and Software, where Services is further clarified into Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services; this segmentation highlights that clients often purchase bundled service models that combine hands-on site support with centralized analytics to maintain consistency across global sites. Based on Modality, the landscape encompasses Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, each modality presenting unique acquisition protocols, quality controls, and analytic needs that affect vendor selection and training requirements.

Therapeutic nuance matters as well; based on Therapeutic area, studies span Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, with oncology trials frequently demanding multi-parametric imaging and longer follow-up while neurology trials emphasize standardized cognitive and structural imaging endpoints. Based on End-User, the ecosystem includes Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, where each end-user brings its own procurement cadence, regulatory expectations, and appetite for innovation. For instance, academic centers may prioritize methodological rigor and novel biomarkers, whereas commercial sponsors often emphasize scalability, cost predictability, and time to readout.

Taken together, these segmentation vectors underscore the importance of flexible service architectures, modality-specific standard operating procedures, and targeted client engagement models that align technical capabilities with therapeutic intent and end-user requirements. Strategic vendors and sponsors that tailor their offerings across these dimensions achieve higher operational efficiency and better alignment with trial goals.

How regional infrastructure, regulatory diversity, and operational capacity across major global regions influence clinical trial imaging strategy and execution

Regional dynamics exert a material influence on imaging operations, vendor ecosystems, and regulatory interactions, with distinct regional patterns in capacity, infrastructure, and collaborative networks. In the Americas, advanced imaging infrastructure, a large base of imaging core laboratories, and high adoption of digital workflows support complex, multi-center trials; however, operational challenges include geographic distances, variable site capabilities, and the need for robust standardization across heterogeneous clinical settings. Consequently, sponsors often favor centralized reading combined with regional technical support to balance quality and logistics.

In Europe, Middle East & Africa, regulatory diversity and variable imaging infrastructure necessitate meticulous harmonization of protocols, translation of standard operating procedures across languages, and careful site qualification processes. The region benefits from strong academic centers and established collaborative research networks, which facilitate multi-country studies if sponsors invest in upfront training and platform interoperability. In addition, regional vendors often provide valuable localized technical support and faster equipment deployment timelines.

In Asia-Pacific, rapid investments in imaging hardware, expanding clinical research capacity, and growing local CRO capabilities have increased the region's appeal for large-scale trials. Nevertheless, differences in clinical practice patterns, data protection frameworks, and modality penetration require tailored imaging strategies that emphasize early site assessment and scalable cloud-based solutions. Across all regions, success depends on proactive local engagement, standardized acquisition protocols, and robust QA programs that bridge regional variability and preserve data integrity for pooled analyses.

Competitive landscape insights showing how specialized providers, software innovators, core labs, and CRO alliances create differentiated end-to-end imaging solutions for trials

Competitive dynamics in clinical trial imaging reflect a blend of specialized service providers, software innovators, imaging core labs, and integrated vendor alliances that together shape service delivery models. Leading imaging organizations differentiate by offering validated reading platforms, modality-specific expertise, and consultative trial design services that help sponsors translate clinical hypotheses into robust imaging endpoints. At the same time, software companies that deliver scalable analytics, secure cloud storage, and regulatory-grade audit trails are increasingly central to multi-vendor orchestration and data governance.

Partnerships between imaging services and technology firms are common, enabling an end-to-end proposition that combines site training, centralized reads, and advanced post-processing. Contract Research Organizations expand their portfolios by incorporating imaging capabilities either organically or through strategic alliances, thereby offering sponsors single-vendor solutions that streamline vendor management. Academic centers and specialty research institutes continue to contribute methodological innovation and validation studies that inform best practices and regulatory dialogue.

For purchasers, competitive evaluation should prioritize demonstrated modality experience, validated analytic pipelines, regulatory compliance history, and the operational capacity to support global trials. Vendors that can demonstrate cross-modal interoperability, transparent quality metrics, and customizable service tiers generally hold a competitive edge. Ultimately, the market favors collaborators who can reduce complexity, provide traceable audit trails, and align technical delivery with clinical objectives.

Actionable strategic moves for imaging program leaders to integrate interoperability, validated analytics, and early protocol alignment to de-risk trials and enhance data utility

Industry leaders should adopt a strategic posture that integrates technological investment, operational rigor, and collaborative partnerships to elevate the effectiveness of clinical trial imaging programs. First, prioritize interoperability by selecting platforms and vendors that support standardized acquisition protocols and secure, auditable data transfer; such choices reduce downstream variability and facilitate pooled analyses. Second, incorporate automated analytics as a complement to expert reads, using validated algorithms to accelerate pre-processing and flag quality issues while preserving blinded adjudication for final endpoint determination.

Next, invest in early-stage imaging strategy development by embedding imaging experts in protocol design to align modality selection, timing of scans, and read paradigms with clinical endpoints and regulatory expectations. This approach minimizes rework and mitigates the risk of unreadable or unusable imaging data. Additionally, cultivate regional supplier networks and flexible contracting terms that account for tariff-related contingencies and localized equipment support, ensuring continuity of imaging capacity across diverse geographies. Finally, establish transparent quality metrics, regular cross-site calibration exercises, and governance mechanisms that assign clear accountability for imaging deliverables. By implementing these measures, sponsors and service providers can reduce operational friction, enhance data integrity, and accelerate the translational value of imaging within clinical programs.

A rigorous mixed-methods approach combining stakeholder interviews, secondary evidence synthesis, and data triangulation to ensure reliable and actionable imaging insights

This research employed a mixed-methods approach to ensure rigor, reproducibility, and relevance for decision-makers. The methodology combined primary qualitative engagement with industry stakeholders, including imaging directors, clinical operations leads, and scientific advisors, with comprehensive secondary analysis of publicly available regulatory guidance, clinical trial registries, technical white papers, and peer-reviewed literature. Primary interviews focused on operational challenges, vendor selection criteria, modality-specific considerations, and regional execution bottlenecks, providing grounded perspectives that contextualize secondary findings.

Data triangulation was applied throughout to validate themes and reconcile divergent viewpoints. The research team synthesized procedural standards, technical specifications, and real-world implementation lessons to produce actionable recommendations. Quality assurance procedures included cross-validation of interview transcripts, consistency checks across data sources, and peer review by domain experts to ensure the reliability of analytical conclusions. Where applicable, methodological caveats and assumptions were documented to help readers interpret findings in light of study scope and the evolving regulatory and technological environment.

Finally, the approach emphasized transparency in data provenance and interpretive steps, enabling readers to trace conclusions back to source inputs and understand how operational realities and technological innovations informed the analytic framework.

Concluding synthesis of how integrated imaging strategy, validated analytics, and operational resilience together determine trial success and evidence credibility

Clinical trial imaging now occupies a central role in the evidence generation pathway, offering objective, reproducible measures that support clinical decision-making and regulatory dialogue. The interplay of advanced modalities, automated analytics, and integrated service models creates opportunities to enhance endpoint sensitivity, reduce variability, and accelerate time to meaningful readouts. At the same time, operational complexity-driven by modality heterogeneity, regional differences, and evolving trade considerations-demands deliberate planning, vendor governance, and investment in interoperable systems.

Looking ahead, organizations that prioritize early integration of imaging strategy into protocol design, adopt validated analytics responsibly, and cultivate resilient supplier networks will be better positioned to harness imaging as a strategic differentiator. In parallel, rigorous quality assurance, transparent performance metrics, and close collaboration with regulatory and scientific stakeholders will remain essential to translating imaging data into credible clinical evidence. Collectively, these actions will strengthen the role of imaging across therapeutic areas and end-users, delivering clearer, more reliable outcomes for both clinical programs and broader health system stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms for automated lesion quantification in oncological imaging trials
  • 5.2. Adoption of cloud-based imaging data platforms to enable decentralized clinical trial workflows across global sites
  • 5.3. Development of quantitative imaging biomarkers for early detection of cardiovascular treatment efficacy in trials
  • 5.4. Emergence of hybrid PET/MRI protocols for enhanced multiparametric assessment in neurodegenerative disorder studies
  • 5.5. Implementation of real-time mobile imaging devices for remote patient monitoring in decentralized clinical trials
  • 5.6. Evolution of regulatory frameworks for standardized imaging endpoint validation in multinational drug development studies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Clinical Trial Imaging Market, by Product & Service

  • 8.1. Services
    • 8.1.1. Operational Imaging Services
    • 8.1.2. Read Analysis Services
    • 8.1.3. System & Technical Support Services
    • 8.1.4. Trial Design & Consulting Services
  • 8.2. Software

9. Clinical Trial Imaging Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Echocardiography
  • 9.3. Magnetic Resonance Imaging
  • 9.4. Positron Emission Tomography
  • 9.5. Ultrasound
  • 9.6. X-Ray

10. Clinical Trial Imaging Market, by Therapeutic area

  • 10.1. Endocrinology
  • 10.2. Immunological Disorder
  • 10.3. Infectious Diseases
  • 10.4. Neurology
  • 10.5. Oncology

11. Clinical Trial Imaging Market, by End-User

  • 11.1. Academic & Government Research Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. Clinical Trial Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Clinical Trial Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Clinical Trial Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alimentiv Inc.
    • 15.3.2. Anagram 4 Clinical Trials
    • 15.3.3. Biospective Inc.
    • 15.3.4. Boston Imaging Core Lab LLC
    • 15.3.5. Cardiovascular Imaging Technologies LLC
    • 15.3.6. Clario
    • 15.3.7. GE HealthCare Technologies Inc.
    • 15.3.8. Icon PLC
    • 15.3.9. Image Core Lab Private Limited
    • 15.3.10. Imaging Endpoints II LLC
    • 15.3.11. Ixico PLC
    • 15.3.12. Median Technologies
    • 15.3.13. Medical Metrics Inc. by Catalent, Inc.
    • 15.3.14. Medidata by Dassault Systemes
    • 15.3.15. Medpace, Inc.
    • 15.3.16. Micron Inc.
    • 15.3.17. Perceptive Informatics LLC
    • 15.3.18. ProScan Imaging LLC
    • 15.3.19. Resonance Health Ltd.
    • 15.3.20. Voiant Clinical
    • 15.3.21. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CLINICAL TRIAL IMAGING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 253. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 256. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 257. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 258. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 259. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 260. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 261. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 262. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 263. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 289. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 292. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 293. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 294. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 295. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 296. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 297. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 298. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 299. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 304. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 305. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 306. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 307. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 308. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 309. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 310. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 311. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY PRODUCT & SERVICE, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2025-2032 (USD MI